Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DXS InternationalAQSE:DXSP +18.52% 3-Year ROIIC % is 0.00 as of Apr. 2025. The stock has 2 warning signs investors should review. Among 618 Healthcare Providers & Services companies, DXS International ranks worse than 161812.14% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
DXS International's 3-Year ROIIC % for the quarter that ended in Apr. 2025 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for DXS International's 3-Year ROIIC % or its related term are showing as below:
AQSE:DXSP's 3-Year ROIIC % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 3.37 * Ranked among companies with meaningful 3-Year ROIIC % only.
DXS International (AQSE:DXSP) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
DXS International 3-Year ROIIC % Related Terms
DXS International 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for DXS International's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSE:DXSP vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, DXS International's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DXS International 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DXS International's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where DXS International's 3-Year ROIIC % falls into.
DXS International's 3-Year ROIIC % for the quarter that ended in Apr. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.0700341 (Apr. 2025) - -0 (Apr. 2022) )
/
( 1.937 (Apr. 2025) - 5.67 (Apr. 2022) )
=
/
-3.733
=
0.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
DXS International (AQSE:DXSP) has a 3-Year ROIIC % of 0.00 as of Apr. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on DXS International and its competitors. Over the past decade, DXS International's 3-Year ROIIC % has ranged from 20.53 to 29.35. According to the industry distribution chart, DXS International ranks #999999 out of 618 companies in the Healthcare Providers & Services industry.
Is DXS International's 3-Year ROIIC % too high?
DXS International's current 3-Year ROIIC % is 0.00. Over the past 10 years, this metric has ranged from a low of 20.53 to a high of 29.35. Based on the distribution chart, DXS International ranks #999999 out of 618 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does DXS International's 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #999999 out of 618 companies for 3-Year ROIIC %. This places DXS International in the lower half of its industry. The industry median 3-Year ROIIC % is 3.37. Historically, DXS International's own 3-Year ROIIC % has ranged from 20.53 to 29.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.37, based on 618 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on DXS International and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading 20% below its estimated fair value. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current 3-Year ROIIC % is 0.00 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSE:DXSP has been successfully added to your 
